# DESCRIPTION

## BACKGROUND

- motivate alternative splicing
- introduce ADOA disease

## SUMMARY

- describe method of modulating OPA1 protein expression
- introduce agent or vector encoding agent
- modulate splicing of NMD exon
- modulate level of processed mRNA
- modulate OPA1 protein expression
- define antisense oligomer with sequence identity
- specify targeted portion of pre-mRNA
- define upstream and downstream regions
- specify genomic site GRCh38/hg38
- define intronic region between canonical exonic regions
- specify overlap with NMD exon or intron
- define 5' or 3' NMD exon-intron junction
- specify targeted portion within NMD exon
- define sequence identity to SEQ ID NO: 279
- specify non-sense mediated RNA decay-inducing exon
- define exon-intron junction of exon GRCh38/hg38
- specify OPA1 protein expression
- define full-length or wild-type OPA1 protein
- specify functional OPA1 protein
- define exclusion of NMD exon from pre-mRNA
- specify increase in exclusion of NMD exon
- define increase in level of processed mRNA
- specify increase in expression of OPA1 protein
- define antisense oligomer with sequence identity
- specify gene editing molecule CRISPR-Cas9
- describe method of modulating OPA1 protein expression
- promote exclusion of coding exon from pre-mRNA
- specify targeted portion of pre-mRNA
- define coding exon with sequence identity
- specify targeted portion within coding exon
- summarize method
- motivate OPA1 protein
- describe agent
- describe OPA1 protein expression
- describe functional OPA1 protein
- describe NMD exon
- describe antisense oligomer
- describe gene editing molecule
- describe CRISPR-Cas9
- describe method of modulating OPA1 protein
- describe coding exon
- describe target portion of pre-mRNA
- describe inclusion of coding exon
- describe method of modulating target protein
- describe exclusion of coding exon and NMD exon
- describe agent binding
- describe modulation of splicing factor
- describe targeted portion of pre-mRNA
- summarize embodiments of coding exon
- specify targeted portion of pre-mRNA
- describe exclusion of coding exon
- specify increase in processed mRNA level
- describe increase in target protein expression
- specify OPA1 protein as target protein
- describe functional OPA1 protein
- specify antisense oligomer as agent
- describe gene editing molecule as agent
- specify CRISPR-Cas9 as gene editing molecule
- describe backbone modification of antisense oligomer
- specify phosphorothioate linkage or phosphorodiamidate linkage
- describe sugar moiety modification of antisense oligomer
- specify length of antisense oligomer
- describe viral vector encoding agent
- specify adenoviral vector, AAV vector, lentiviral vector, HSV vector, or retroviral vector
- describe assessing mRNA level or expression level of OPA1 protein
- specify therapeutic agent
- describe pharmaceutical composition
- specify antisense oligomer with at least 80% sequence identity
- describe composition with backbone modification, sugar moiety modification, or combination
- specify pharmaceutical composition promoting exclusion of coding exon
- describe pharmaceutical composition promoting exclusion of both coding exon and NMD exon
- specify formulation for administration
- describe method of treating disease or condition
- specify disease or condition associated with loss-of-function mutation in OPA1 gene
- specify disease or condition associated with haploinsufficiency of OPA1 gene
- describe eye disease or condition
- specify various diseases or conditions
- describe method of treating optic atrophy type 1
- describe method of treating autosomal dominant optic atrophy
- specify disease or condition associated with autosomal recessive mutation of OPA1 gene
- describe subject as human or non-human animal
- specify administration route
- describe ex vivo cells
- specify therapeutic agent administration
- describe treatment of disease or condition
- summarize method of treating disease or condition

## DETAILED DESCRIPTION

- introduce alternative splicing events in OPA1 gene
- describe therapeutic agents for modulating alternative splicing

### mRNA Splicing

- describe mRNA splicing process
- introduce spliceosome complex
- explain 5′ splice site recognition
- explain 3′ splice site recognition
- describe U2AF protein function
- introduce intronic and exonic splicing enhancers/silencers
- explain stochastic nature of splicing decisions
- describe role of cis-acting auxiliary elements
- introduce trans-acting RNA-binding proteins
- explain function of SR proteins
- describe repressive effects of ESSs
- introduce alternative splicing process
- describe inclusion/exclusion of exons
- explain production of multiple protein isoforms
- introduce alternatively spliced exons
- describe regulation of alternative splicing
- explain nonsense-mediated mRNA decay (NMD) pathway
- introduce NMD-inducing exons (NIEs)
- describe cryptic splice sites
- explain identification of splice sites and regulatory sequences

### Target Transcripts

- exploit NMD exon in OPA1 pre-mRNA
- induce exon skipping of NMD exon
- inhibit NMD pathway
- increase OPA1 protein in patient cells
- alleviate symptoms of OPA1 deficiency
- exploit alternative splicing of OPA1 pre-mRNA
- modulate OPA1 protein expression level
- target coding exon of OPA1 pre-mRNA
- promote exclusion of coding exon
- increase OPA1 protein expression
- modulate levels of alternatively spliced mRNA transcripts
- translate mature OPA1 mRNA into different OPA1 proteins
- alleviate symptoms of OPA1 deficiency
- treat diseases not directly associated with OPA1
- target protein not directly associated with disease
- modulate expression of target protein
- provide therapeutic agent
- target OPA1 mRNA transcripts
- modulate splicing or protein expression level
- target NMD exon of OPA1 pre-mRNA
- target sequence within NMD exon
- target sequence upstream from 5' end of NMD exon
- target sequence downstream from 3' end of NMD exon
- target sequence within intron flanking NMD exon
- target sequence comprising NMD exon-intron boundary
- target sequence within exon of OPA1 pre-mRNA
- target sequence within intron of OPA1 pre-mRNA
- target sequence comprising both intron and exon
- target specific regions of OPA1 pre-mRNA
- target exon 6x, 7x, or 28x of OPA1 pre-mRNA
- target specific sequences upstream or downstream from exon
- provide ASO with specific sequence complementary to target
- define target transcripts
- specify ASO targets
- describe exon-intron boundary targets
- describe NMD exon targets
- describe pseudo-exon targets
- describe coding exon targets
- specify upstream targets
- specify downstream targets
- describe intron targets
- describe exon targets
- describe targets with sequence identity
- specify exon 7 targets
- specify other coding exon targets
- describe upstream distance targets
- describe downstream distance targets
- specify maximum upstream distance targets
- specify maximum downstream distance targets
- describe ASO sequence complementarity
- describe upstream coding exon targets
- describe exon-intron boundary targets
- describe downstream coding exon targets
- describe coding exon targets with sequence identity
- describe upstream targets with sequence identity
- describe downstream targets with sequence identity
- describe exon-intron boundary targets with sequence identity
- describe ASO targets with sequence identity

### Protein Expression

- define functional OPA1 protein
- define partially functional OPA1 protein
- describe method to increase OPA1 protein production
- motivate haploinsufficiency of OPA1 protein
- describe antisense oligomer binding to OPA1 pre-mRNA
- induce exon skipping of pseudo-exon
- increase mature mRNA encoding functional OPA1 protein
- increase OPA1 protein expression in cells
- describe autosomal recessive inheritance
- describe autosomal dominant inheritance
- use ASO to increase protein or functional RNA expression
- target pre-mRNA transcript encoding disease-causative protein
- target NMD exon-containing pre-mRNA transcript
- induce skipping of NMD exon or coding exon
- describe subject with mutant alleles
- bind ASO to targeted portion of pre-mRNA
- increase mRNA encoding OPA1 protein

### Exon Inclusion

- define NMD exon-containing pre-mRNA
- describe alternative splicing
- introduce pseudo-exon inclusion
- explain NMD of mature mRNA
- describe aberrant protein expression
- identify most abundant pseudo-exon
- describe antisense oligomer targeting
- induce exon skipping
- calculate percent exon inclusion
- provide ENCODE data
- describe ASO-mediated protein increase
- specify protein increase percentage
- describe mRNA increase
- specify mRNA increase percentage
- describe control compound
- define NMD exon length
- describe intron retention
- describe 5' end portion of intron
- describe 3' end portion of intron
- describe portion within intron
- specify NMD exon length range
- describe frameshift and PIC
- describe non-productive mRNA
- describe PIC position
- provide OPA1 exon examples
- introduce method of modulating OPA1 protein expression
- describe agent binding to pre-mRNA
- promote inclusion of coding exon
- specify target portion of pre-mRNA
- describe coding exon sequence identity
- specify genomic site
- describe increase in coding exon inclusion

### Exclusion of Both NMD Exon and Coding Exon

- introduce method of modulating expression of target protein
- describe contacting agent to cell
- explain promotion of exclusion of coding exon and NMD exon
- detail increase in level of processed mRNA
- specify binding of agent to targeted portion of pre-mRNA
- describe modulation of binding of factor involved in splicing
- explain interference with binding of factor
- specify location of NMD exon
- describe targeted portion of pre-mRNA proximal to coding exon
- specify location of targeted portion within intronic region
- detail targeted portion within coding exon
- specify targeted portion within region spanning upstream of coding exon
- describe targeted portion proximal to NMD exon
- specify location of targeted portion within intronic region of NMD exon
- detail targeted portion within NMD exon
- specify targeted portion within region spanning upstream of NMD exon
- describe applicability to modulation of OPA1 protein expression
- specify sequence identity of coding exon and NMD exon
- detail increase in exclusion of coding exon and NMD exon
- explain increase in level of processed mRNA and OPA1 protein expression

### Therapeutic Agents

- provide therapeutic agents to modulate OPA1 protein expression
- define NIE repressor agent
- describe polynucleic acid polymer composition
- motivate treatment of OPA1 protein deficiency
- describe method of treatment or prevention
- administer NIE repressor agent to increase functional OPA1 protein
- bind agent to region of pre-mRNA transcript
- decrease inclusion of NMD exon in mature transcript
- specify binding to intron containing NMD exon
- specify binding to NMD exon-activating regulatory sequence
- describe reduction of NMD exon inclusion
- specify percentage reduction of NMD exon inclusion
- motivate treatment of functional OPA1 protein deficiency
- administer agent to increase functional OPA1 protein
- bind agent to region of pre-mRNA transcript
- decrease inclusion of coding exon in mature transcript
- specify binding to region containing coding exon
- describe increase of active OPA1 protein levels
- specify percentage increase of active OPA1 protein
- describe polynucleic acid polymer length
- specify sequence complementarity of polynucleic acid polymer
- describe hybridization of polynucleic acid polymer
- specify sequence identity of polynucleic acid polymer
- describe tolerance of substitutions in polynucleic acid polymer
- determine sequence identity by BLAST alignment
- provide composition comprising antisense oligomer
- induce exon skipping by binding to targeted portion of OPA1 pre-mRNA
- describe design of antisense oligomer
- define ASO hybridization
- describe Tm of hybridization
- define complementary oligomers
- describe sequence complementarity
- define ASO composition
- describe backbone structure
- list backbone modifications
- describe stereochemistry of phosphorus linkages
- describe diastereomeric purity
- describe Rp and Sp configurations
- describe nonrandom mixture of Rp and Sp
- describe ASO sequence identity
- describe Rp and Sp percentages
- describe sugar moiety modifications
- list sugar moiety modifications
- describe uniform modifications
- describe mixed modifications
- describe backbone and sugar moiety modifications
- describe 2'MOE modification and phosphorothioate backbone
- describe phosphorodiamidate morpholino (PMO)
- describe peptide nucleic acid (PNA)
- describe modification of ASO components
- describe enhancing binding affinity
- describe reducing binding to non-target sequences
- describe reducing degradation by nucleases
- describe improving uptake into cells and nuclei
- describe altering pharmacokinetics and pharmacodynamics
- describe modulating half-life
- describe MOE phosphorothioate-modified nucleotides
- describe advantages of MOE-modified nucleotides
- describe synthesizing ASOs
- define nucleic acid directions
- define upstream and downstream regions
- describe ASO binding to OPA1 pre-mRNA
- specify ASO binding regions downstream of 5' splice site
- list specific binding regions downstream of 5' splice site
- specify ASO binding regions upstream of 5' splice site
- list specific binding regions upstream of 5' splice site
- describe ASO binding to OPA1 pre-mRNA upstream of 3' splice site
- specify ASO binding regions upstream of 3' splice site
- list specific binding regions upstream of 3' splice site
- describe ASO binding to OPA1 pre-mRNA downstream of 3' splice site
- specify ASO binding regions downstream of 3' splice site
- list specific binding regions downstream of 3' splice site
- specify targeted portion of OPA1 pre-mRNA
- describe targeted portion within NMD exon
- describe targeted portion at pseudo-exon and intron boundary
- specify ASO length
- list specific ASO lengths
- specify ASO length ranges
- list specific ASO length ranges
- specify ASO length of 8-50 nucleobases
- specify ASO length of more than 50 nucleobases
- specify ASO length of 8-40 nucleobases
- specify ASO length of 8-35 nucleobases
- specify ASO length of 8-30 nucleobases
- specify ASO length of 8-25 nucleobases
- specify ASO length of 8-20 nucleobases
- introduce therapeutic agents
- describe ASO chemistries
- describe ASO conjugates
- describe targeted nucleic acid
- describe cell types
- introduce pharmaceutical compositions
- describe composition preparation
- describe pharmaceutically acceptable salts
- describe salt preparation
- list examples of salts
- describe dosage forms
- describe suspension formulations
- describe therapeutic agents
- introduce liposomes
- describe sterically stabilized liposomes
- describe surfactants
- describe penetration enhancers
- describe combination therapies
- introduce additional therapeutic agents
- describe small molecules
- describe antisense oligonucleotides
- describe treatment of subjects
- define individual
- describe administration methods
- describe treatment of diseases
- describe OPA1 deficiency
- describe eye diseases
- describe Optic atrophy type 1
- describe mitochondrial disorders
- describe gene editing tools
- describe viral vectors
- describe administration routes
- describe blood-brain barrier penetration
- describe evaluation methods

### Methods of Identifying Additional ASOs That Induce Exon Skipping

- introduce method for identifying ASOs
- motivate pseudo-exon skipping
- describe ASO walk method
- design ASOs for target region
- tile ASOs every 5 nucleotides
- deliver ASOs to disease-relevant cell line
- assess exon skipping effects
- describe ASO micro-walk method
- refine nucleotide acid sequence
- explore regions with ASO micro-walk
- assess splicing-inducing effects
- test ASOs in vivo using animal models
- administer ASOs by various routes
- assess effect of ASO treatment
- validate NMD-inducing exon with NMD inhibitor

### Specific Embodiments (a)

- define method of treating Optic atrophy type 1
- specify target protein as OPA1
- describe method of increasing OPA1 protein expression
- exclude non-sense mediated RNA decay-inducing exon
- specify target protein without non-sense mediated RNA decay-inducing exon
- describe full-length target protein
- specify antisense oligomer (ASO) as therapeutic agent
- specify pre-mRNA as target
- describe contacting therapeutic agent with nucleus of cell
- correct deficiency in target protein or functional RNA
- specify cells in or from subject with condition caused by OPA1 deficiency
- describe haploinsufficiency of target protein
- specify subject with condition caused by disorder resulting from target protein deficiency
- describe target protein with reduced function
- describe target protein with full function
- specify targeted portion within non-sense mediated RNA decay-inducing exon
- specify targeted portion upstream or downstream of non-sense mediated RNA decay-inducing exon
- describe NMD exon mRNA with sequence identity to SEQ ID NO: 2 or 3
- describe genetic sequence with sequence identity to SEQ ID NO: 1
- describe targeted portion with sequence identity to region of SEQ ID NO: 2 or 3
- describe ASO with sequence complementary to SEQ ID NO: 2 or 3
- specify targeted portion within specific exons of OPA1
- specify targeted portion upstream or downstream of specific exons of OPA1
- describe targeted portion at exon-intron junction of OPA1
- describe full-length protein or wild-type protein production
- describe increase in mRNA encoding target protein or functional RNA
- describe increase in target protein production
- specify administration of therapeutic agent
- define specific embodiments
- specify therapeutic agent
- describe antisense oligomer
- outline pharmaceutical composition
- detail method of treating subject
- specify administering method
- describe composition for treating optic atrophy
- outline composition for increasing expression
- specify therapeutic agent for treating condition
- describe composition for treating disease or disorder
- specify OPA1 protein and NMD exon mRNA
- describe exclusion of non-sense mediated RNA decay-inducing exon
- outline composition for treating optic atrophy type 1
- specify full-length OPA1 protein
- describe antisense oligomer targeting NMD exon mRNA
- outline composition for treating condition associated with OPA1 protein
- specify sequence identity to SEQ ID NO: 2 or 3
- describe targeted portion of NMD exon mRNA
- outline composition for treating subject with antisense oligomer
- specify pharmaceutical composition with excipient
- define specific embodiments
- specify targeted portion of NMD exon mRNA
- specify OPA1 NMD exon mRNA transcript
- specify antisense oligomer backbone modification
- specify antisense oligomer composition
- specify antisense oligomer length
- specify antisense oligomer sequence identity
- specify targeted portion of OPA1 NMD exon mRNA transcript
- specify pharmaceutical composition formulation
- specify method of administering second therapeutic agent
- specify second therapeutic agent
- specify method of correcting intron retention
- describe method of inducing processing of deficient OPA1 mRNA transcript
- describe method of treating condition caused by deficient OPA1 protein
- describe method of treating Optic atrophy type 1
- describe method of increasing expression of OPA1 protein
- specify agent that modulates splicing of NMD exon mRNA
- describe method of modulating expression of target protein
- describe method of treating disease or condition
- specify therapeutic agent that modulates splicing of NMD exon
- specify targeted portion of mRNA encoding target protein
- specify distance of targeted portion from NMD exon
- specify genomic site of targeted portion
- specify location of targeted portion in intronic region
- specify overlap of targeted portion with NMD exon or intron
- specify composition of targeted portion
- specify sequence identity of targeted portion
- specify mRNA encoding target protein
- specify sequence identity of mRNA encoding target protein
- specify embodiments
- define mRNA encoding target protein
- specify sequence identity
- define targeted portion of mRNA
- specify antisense oligomer
- define non-sense mediated RNA decay-inducing exon
- specify exon-intron junction
- define full-length protein
- promote exclusion of NMD exon
- increase expression of target protein
- specify therapeutic agent
- increase level of processed mRNA
- specify disease or condition
- specify loss-of-function mutation
- specify haploinsufficiency
- specify Optic atrophy type 1
- promote exclusion of NMD exon and increase expression
- inhibit exclusion of NMD exon
- decrease expression of target protein
- specify gain-of-function mutation
- specify allele encoding mutant target protein
- inhibit exclusion of NMD exon and decrease expression
- specify backbone modification
- specify phosphorodiamidate morpholino
- specify modified sugar moiety
- specify length of antisense oligomer
- specify complementary antisense oligomer
- assess mRNA level or expression level

### Further Specific Embodiments

- define embodiment 1
- specify agent composition
- specify embodiment 2
- specify agent binding
- specify agent modulation
- specify embodiment 3
- specify agent interference
- specify embodiment 4
- specify targeted portion proximity
- specify embodiment 5
- specify targeted portion distance
- specify embodiment 6
- specify targeted portion distance
- specify embodiment 7
- specify targeted portion distance
- specify embodiment 8
- specify targeted portion distance
- specify embodiment 9
- specify targeted portion location
- specify embodiment 10
- specify targeted portion location
- specify embodiment 11
- specify targeted portion location
- specify embodiment 12
- specify targeted portion location
- specify embodiment 13
- specify targeted portion location
- specify further embodiments
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify targeted portion of pre-mRNA
- specify method of modulating expression
- specify embodiment 90
- specify embodiment 91
- specify embodiment 92
- specify embodiment 93
- specify embodiment 94
- specify embodiment 95
- specify embodiment 96
- specify embodiment 97
- specify embodiment 98
- specify embodiment 99
- specify embodiment 100
- specify embodiment 101
- specify embodiment 102
- specify embodiment 103
- specify embodiment 104
- specify embodiment 105
- specify embodiment 106
- specify embodiment 107
- specify embodiment 108
- specify embodiment 109
- specify embodiment 110
- specify embodiment 111 to 134
- specify embodiment 135
- specify embodiment 136
- specify embodiment 137
- specify embodiment 138
- specify embodiment 139
- specify embodiment 140
- specify embodiment 141
- specify embodiment 142
- specify embodiment 143
- specify embodiment 144
- specify embodiment 145
- specify embodiment 146
- specify embodiment 147
- specify embodiment 148
- specify embodiment 149
- specify embodiment 150
- specify embodiment 151
- specify embodiment 152
- specify embodiment 153
- specify embodiment 154
- specify embodiment 155
- specify embodiment 156
- specify embodiment 157
- specify embodiment 158
- specify embodiment 159-180

## EXAMPLES

- provide examples of NMD-inducing exon inclusion events

### Example 1: Identification of NMD-inducing Exon Inclusion Events in Transcripts by RNAseq using Next Generation Sequencing

- identify NMD exon inclusion events using RNAseq

### Example 2: Confirmation of NMD Exon via Cycloheximide Treatment

- confirm NMD exon via cycloheximide treatment

### Example 3: NMD Exon Region ASO Walk

- perform ASO walk for NMD exon region

### Example 4: NMD Exon Region ASO Walk Evaluated by RT-PCR

- evaluate ASO walk sequences by RT-PCR

### Example 5: NMD Exon Region ASO Microwalk Evaluated by RT-qPCR

- evaluate ASO microwalk sequences by RT-qPCR

### Example 6: Dose-Dependent Effect of Selected ASO in CXH-Treated Cells

- show dose-dependent effect of selected ASO

### Example 7: Intravitreal (IVT) Injection of Selected ASOs

- inject ASOs intravitreally

### Example 8: Intracerebroventricular (ICV) Injection of Selected ASOs

- inject ASOs intracerebroventricularly

### Example 9: OPA1 Non-Productive Splicing Event Identification and Validation

- identify nonsense mediated decay exon inclusion event
- describe non-productive mRNA transcript degradation
- evaluate true abundance of event using cycloheximide
- show increase in OPA1 transcripts containing NMD exon
- validate presence of NMD exon in other ocular cell lines
- introduce Example 10
- show reverse transcription PCR data from primate eyes
- quantify NMD exon abundance at different ages
- introduce Example 11
- transfect antisense oligomers into HEK293 cells
- assess effect on NMD exon using cycloheximide
- quantify non-productive splicing and productive OPA1 mRNA levels
- introduce Example 12
- transfect different doses of ASO-14 into HEK293 cells
- analyze impact on non-productive OPA1 mRNA and OPA1 mRNA expression
- show western blots of OPA1 protein expression
- introduce Example 13
- generate OPA1 haploinsufficient cell line using CRISPR-Cas9
- transfect different doses of ASO-14 into OPA1+/- HEK293 cells
- analyze impact on OPA1 protein levels
- introduce Example 14
- describe ASO treatment and RNA analysis
- show gel image of RT-PCR products
- quantify qPCR Ct values for different reactions
- show relative amount of corresponding transcripts
- show OPA1 expression level after ASO treatment
- describe microwalk experiment
- show Ct values for qPCR reaction
- quantify relative amount of OPA1 transcripts
- show Ct values for RPL32 transcripts
- describe experiment with 16-mers
- show Ct values for qPCR reaction
- quantify relative amount of OPA1 transcripts
- show Ct values for RPL32 transcripts
- describe dose response experiment
- show dose response curves of relative amounts of OPA1 transcripts
- describe ATP measurement experiment
- show ATP level measured under each condition
- show OPA1 protein under each condition
- describe experiment with OPA1 mutations from diagnosed patients
- show mRNA and protein expression of OPA1 gene in patient cells
- show effects of ASO-14 on OPA1 NMD exon inclusion
- show effects of ASO-14 on OPA1 mRNA level
- show effects of ASO-14 on OPA1 protein level
- describe experiment with patient fibroblast cells
- show deficiencies in mitochondrial bioenergetics
- show effects of ASO-14 on mitochondrial energetics in F35 patient cells
- show effects of ASO-14 on mitochondrial energetics in F36 patient cells
- summarize preclinical data
- describe TANGO disease modifying approach
- provide concluding remarks

